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INTRODUCTION 
 The combination of obstructive sleep apnea and metabolic syndrome has 
been termed as syndrome z.Sleep related breathing disorders and metabolic 
syndrome are on increasing trend because of epidemic of obesity.(1) Beyond 
their epidemiologic relationship, growing evidence suggests that OSA may be 
causally related to metabolic syndrome. Its prevalence varies from 74 to 85% 
among patients with obstructive sleep apnea and from 37 to 41% among 
patients with nonobstructive sleep apnea.( 2) 
 Metabolic syndrome 
 The National Cholesterol Education Program Adult Treatment Panel III 
(NCEP ATP III) report2 defines metabolic syndrome as three or more of the 
following five variables: hypertension, increased fasting blood glucose, low 
high-density lipoprotein cholesterol (HDL-C), elevated serum triglyceride, and 
abdominal obesity. (3) 
Obstructive sleep apnea  
 Obstructive sleep apnea syndrome is characterized by repetitive 
episodes of upper airway obstruction that occur during sleep, usually associated 
with a reduction in blood oxygen saturation.(4) Structural factors like increased 
volume of tongue, lateral pharyngeal wall and soft tissue are significant risk 
factors for OSA. OSA patients have anatomically small pharyngeal airways.(5).  
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 In patients with OSA during wakefulness there will be increased 
pharyngeal dilator muscle activity due to long time neuromuscular 
compensation. That compensation will be reduced during sleep in patients with 
OSA combined with reduced reflex activity of muscles during sleep causing 
airway collapse in apneic patients. This can lead to a combination of 
hypopneas, reduction in airflow associated with a fall in oxygen saturation, or 
apneas, complete cessation of airflow.(6) 
Polysomnographic features of OSA 
 An apnea has been defined as > 90 percent reduction from baseline in 
oronasal thermister airflow. Hypopnea has been defined as an event lasting > 
10 sec characterized by > 30 percent reduction from baseline in peak nasal 
inspiratory airflow associated with > 4 percent reduction in arterial s02 from 
baseline. RERA has been defined as sequence of breaths not meeting citeria for 
apnea or hypopnea but causing increased respiratory effort or inspiratory 
flattening leading to arousal. OSA severity is usually determined as follows: 
AHI 5-15 indicates mild, 15-30 moderate and over 30 severe OSAS. In an 
urban setting in northern India, the prevalence of obstructive sleep apnea and 
the obstructive sleep apnea syndrome is reported to be 13.7% and 3.8%, 
respectively.(7) 
   Polysomnographic monitoring of obstructive sleep apnea syndrome 
should consist of monitoring of sleep by electroencephalography, 
electrooculography, electromyography, airflow, and respiratory muscle effort, 
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and should also include measures of electrocardiographic rhythm and blood 
oxygen saturation.  
Changes in cardiac rhythm, particularly bradytachycardia, frequently 
occur with the apneic episodes. The arterial oxygen saturation level falls during 
the apneic episode and rises to baseline levels at the termination of the apneic 
episode. Due to a 10- to 20-second delay in detection of oxygen saturation by 
subcutaneous monitoring devices, a dissociation may occur between the 
respiratory patterns and the oxygen-saturation patterns seen on the 
polysomnogram. Carbon dioxide values in the blood are usually only 
transiently elevated, but sustained elevations can be seen in some patients.  
 The obstructive apneic episodes can lead to gastroesophageal reflux in 
some patients; reflux can be detected during sleep by intraesophageal pH 
monitoring. Sleep is disrupted by arousals that usually occur at the termination 
of the apneic events, resulting in excessive daytime sleepiness, which may be 
detected by either the multiple sleep latency test (MSLT) or other tests of 
daytime alertness and sleepiness. Mean sleep latencies on the MSLT are often 
below 10 minutes and can be below 5 minutes (normal 10 to 20 minutes). 
Sleep-onset REM periods during the naps are not typical, but sleep-onset REM 
periods can occur on every nap.(4)  
Other Laboratory Test Features 
 Awake arterial blood gas measurements are usually normal, but some 
patients with severe obstructive sleep apnea syndrome can show abnormal 
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values. Cephalometric radiographs, magnetic resonance imaging, computed 
tomographic scanning of the upper airways or fibreoptic endoscopy can show 
obstruction of the upper airway. Cardiac testing may show evidence of 
impaired right ventricular function in some patients with severe obstructive 
sleep apnea syndrome. Hematologic studies may also show an elevated 
hemoglobin or hematocrit value, indicating polycythemia.(4)  
Diagnostic Criteria: Obstructive Sleep Apnea Syndrome 
  A. The patient has a complaint of excessive sleepiness or insomnia. 
Occasionally, the patient may be unaware of clinical features that are observed 
by others. 
B. Frequent episodes of obstructed breathing occur during sleep.  
C. Associated features include:  
  1. Loud snoring 
  2. Morning headaches  
  3. A dry mouth upon awakening  
  4. Chest retraction during sleep in young children  
D. Polysomnographic monitoring demonstrates:  
1.  More than five obstructive apneas, greater than 10 seconds in duration, 
per hour of sleep and one or more of the following:  
  a. Frequent arousals from sleep associated with the apneas  
 b. Bradytachycardia 
  c. Arterial oxygen desaturation in association with the apneic episodes 
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 2.  MSLT may or may not demonstrate a mean sleep latency of less than 10 
minutes.  
E.  The symptoms can be associated with other medical disorders (e.g., 
tonsillar enlargement).  
 F.  Other sleep disorders can be present (e.g., periodic limb movement 
disorder or narcolepsy 
    Although metabolic syndrome and OSA may be coincident syndromes, 
there is growing evidence that the pathophysiology of OSA and metabolic 
syndrome overlap considerably. We are only beginning to understand the 
potential mechanisms underlying the OSA–metabolic syndrome interaction. 
Although there is no clear consensus, there is growing evidence that alterations 
in the hypothalamic–pituitary axis, generation of reactive oxygen species 
(ROS) due to repetitive hypoxia, inflammation, and generation of adipokines 
may be implicated in the changes associated with both OSA and metabolic 
syndrome. Studies on the prevalence of metabolic syndrome and its association 
in patients with OSA in hospital based population in India is limited.  
 Prevalence may differ among the various ethnic groups. Establishing 
prevalence and its association is essential to guide decision making for patients 
with sleep disturbances as these patients probably have higher burden of 
metabolic syndrome and to encourage systemic evaluation for the presence of 
metabolic abnormalities in OSA and vice versa. 
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REVIEW OF LITERATURE 
Definitions of the metabolic syndrome  
The metabolic syndrome is a cluster of abnormalities of metabolism that 
has been found to be associated with a high risk of cardiovascular mortality, 
coronary heart disease and stroke greater than that of its individual components 
[8]. The syndrome itself has been otherwise called by various names, such as 
the insulin resistance syndrome, deadly quartet, syndrome X, syndrome X plus, 
among others.  
The clear definition is essential to compare the prevalence of the 
metabolic syndrome both among populations and over time, inspite of racial 
and ethnic differences. Debate arises when considering definition about giving 
importance to which components of metabolic abnormalities. Before the initial 
WHO definition of the metabolic syndrome in 1998, there is no uniformity in 
defining the prevalence of metabolic syndrome among various races. 
   WHO report 1999 [9], the European Group for the Study of Insulin 
Resistance (EGIR), in 1999, and the definition of the Adult Treatment Panel III 
(ATPIII) also known as National Cholesterol Education Program Expert Panel 
on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adult—
in 2001 [10] are the 2 major recognized definitions of metabolic syndrome. 
   The ATPIII definition of the metabolic syndrome 2001 was more 
suitable for clinical practice. No measurement of insulin resistance was 
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included in ATP 3 definition. As per modified NCEP ATPIII criteria ( 2005 
REVISED definition) metabolic syndrome is defined as three out of five of the 
following features,.Abdominal Obesity( waist circumference >=90 cm for asian 
males,>=80 cm in asian females), Hyperglycemia ( fasting glucose>=100mg/dl 
or on treatment),.Hypertriglyceridemia ( triglyceride >= 150mg/dl or on 
treatment),Decreased HDL cholesterol( <40mg/dl(M), <50mg/dl(F), 
Hypertension.( systolic >= 130mmHg or diastolic >= 85mm Hg)  
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Figure 1 
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Epidemiology of obstructive sleep apnea 
 Defining OSA as an AHI ≥5 events/hour in the Wisconsin Sleep 
Cohort, the prevalence of OSA was 24% in men and 9% in women aged 30-60 
years of age (11). The prevalence of OSA with associated excessive daytime 
somnolence termed as OSAS is approximately 3% to 7% in adult men and  
2% to 5% in adult women (12). Prevalence estimates don’t vary significantly 
worldwide suggesting that OSA is as common in the developing world as in 
western society (13). 
OSA and obesity 
 Obesity, especially central obesity, is one of the strongest risk factors 
for OSA. Given the worsening modern pandemic of obesity, the prevalence of 
OSA is on increasing trend. In the Wisconsin Sleep Cohort study, longitudinal 
analysis over a 4 year period shows 10% increase in body weight confers a 
32% increase in AHI and a 6-fold increase in the risk of developing moderate-
severe OSA. On the other hand, a 10% decrease in weight was associated with 
a 26% decrease in the AHI. Changes in other body composition measures (e.g., 
waist or neck circumference) were not associated with an increase (or decrease) 
in the AHI after accounting for the changes in weight.(14) Recent data also 
suggested that modest changes in weight were related to an increase or 
decrease in SDB, and this association was stronger in men than in women. 
    In the Sleep Heart Health Study, a multi-centre epidemiologic cohort 
study of cardiovascular correlates of OSA in middle-aged and older Americans, 
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weight gain of 10 kilograms over a 5-year period conferred a 5.2- and 2.5-fold 
increase in the likelihood of increasing the AHI by 15 events per hour in men 
and women respectively(11). The prevalence can be as high as 70% in patients 
referred for bariatric surgery.(15)  
 Obesity may alter the normal upper airway mechanics and contribute to 
the pathophysiology of OSA in a number of ways. Obesity is associated with a 
reduction in lung volumes, especially functional residual capacity and 
expiratory reserve volume leading to increased work of breathing.(16) Leptin is 
a hormone produced by adipocytes and it acts on the central respiratory centres 
to stimulate ventilation and leptin deficiency or leptin resistance has been 
associated with hypoventilation.(17) Obesity is characterised by central leptin 
resistance and there is blunting of the response to hypercapnia. This will lead to 
worsening of hypercapnia and impairment of arousal from sleep during 
apneas.(18)  
 Weight loss should be recommended for all overweight or obese 
patients with OSA, as it may confer a benefit in reducing OSA severity, 
Patients with more severe OSA derive more benefit from weight loss than those 
with milder disease and those who lost most of weight get more benefit.  
 Bariatric surgeries are also helpful in OSA patients.(19) In a Swedish 
case-control longitudinal study of more than 3,400 obese patients, the average 
fall in BMI was −9.7±5 kg.m-2 compared to 0±3 kg.m-2 in the control group 
following bariatric surgery. There was also a marked improvement in OSA 
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symptoms and a lower 2-year incidence of T2DM and hypertriglyceridemia 
(20). Laparoscopic adjustable gastric banding in a cohort of severely obese 
patients with moderate to severe OSA resulted in significant weight loss and a 
decrease in AHI when evaluated at an average of 12 - 24 months after 
surgery.(21)  
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Figure 2 
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 Prevalence of metabolic diseases linked to obesity based on ethnicity: 
black (B) vs. white (W). Data were retrieved from the Center for Disease 
Control (CDC), National Health and Nutrition Examination Survey 
(NHANES), the Genetic Epidemiology Network of Arteriopathy (GENOA) 
and the Sleep Heart Health Study (SHHS). 
OSA and sex 
  OSA shows increased prevalence in men with most epidemiological 
studies showing 2 to 3 fold higher prevalence of OSA in men than women. 
(22)Sex hormones may also be reason for that. OSA is more prevalent in post-
menopausal women than pre-menopausal women, and hormone replacement 
therapy in post-menopausal women may protect against the disorder.(23) 
OSA and age 
 The Sleep Heart Health Study demonstrated that the prevalence of OSA 
increases with age and plateau after the age of 60 years, and the cardiovascular 
mortality and other risk factors associated with OSA is mainly limited to 
middle-aged adults, especially men(11). Some studies demonstrated that with 
aging, there is increased deposition of parapharyngeal fat in both sexes; 
lengthening of the soft palate, significantly in women; and a change in the bony 
shape surrounding the pharynx. These physiological and anatomical differences 
could predispose to pharyngeal collapse during sleep (24) Some researchers 
have suggested that the mortality risk with sleep apnea may even decrease in 
the elderly because of adaptive responses to chronic intermittent hypoxia.(25) 
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OSA AND MALLAMPATTI SCORING 
 Patients with OSA have reduced upper airway cross-sectional area 
compared to patients without OSA. These anatomical deficits in the upper 
airway and collapsibility are more likely to be involved in the pathogenesis of 
OSA. Mallampati classification an anesthetic assessment of difficulty in 
intubation risk based on the morphology of the oropharynx, will be a possible 
simple assessment tool for OSA. This simple assessment tool was first 
described by Mallampati et al in 1985 with only 3 grades, but was later 
modified to 4 classes as modified Mallampati class. 
 The assessment is made with the patient sitting with the head in a 
neutral position, the mouth opened, and the tongue protruded maximally 
without phonation. The class is then graded based on the visibility of the 
airway structures 
 Grade I  –  tonsils, pillars and soft palate are all clearly visible;  
Grade II  –  the uvula, pillars and upper pole are visible;  
Grade III  –  only part of the soft palate is visible but the uvula is 
partly obscured, and 
Grade IV  –  only the hard palate is visible.  
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 There may be good inter-observer agreement with the use of this 
classification, especially in more senior clinicians. There is some validation of 
the use of Mallampati class in clinical assessment for sleep apnea.  
  Hiremath et al26 reported that a higher Mallampati class (more 
oropharyngeal crowding) was associated with increased prevalence of both 
OSA and difficult intubation in a cohort of patients undergoing anesthesia. 
Liistro27 reported a significant correlation between AHI and Mallampati class in 
202 subjects undergoing polysomnography, but this association was only 
significant in those with nasal obstruction (62% of the cohort). The odds ratio 
(OR) of an AHI > 15 was 2.45 (95% CI 1.23-4.84) in subjects with nasal 
Figure 3 
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obstruction and a Mallampati class III-IV relative to class I-II. There was no 
increased OR seen in those without nasal obstruction. Yagi et al28 similarly 
reported a statistically significant correlation between Modified Mallampati 
class and AHI in 141 patients. 
 Morinaga et al29 from the same institution also reported on the clinical 
utility of the Modified Mallampati class, but this time assessed the changes in 
AHI following nasal surgery. This group reported that improvements in AHI 
were negatively correlated with the Mallampati class, that is, higher degrees of 
oropharyngeal crowding were associated with lesser changes in AHI after nasal 
surgery. Nuckton et al30 prospectively assessed 137 patients attending a sleep 
clinic and reported an OR for OSA (defined as an AHI ≥ 5) of 2.5 (95% 
confidence interval [CI] 1.2-3.2) for each point increase in Mallampati class. 
The OR for Mallampati class was higher more than those of witnessed apneas 
and neck circumference. The authors concluded that the Mallampati class was a 
useful component of the clinical examination that had clinical value in 
predicting the presence of severity of OSA. 
Ramachandran et al31 recently reported on Mallampati class as a 
component of a multi-variate prediction score derived from a large 
retrospective cohort of patients undergoing surgery and validated prospectively 
in a sleep clinic population. Although the primary variable was a multi-variate 
prediction score, this group reported that Mallampati class III or IV was  
an independent predictor of an AHI > 5 with a hazard ratio of 2.7  
(95% CI 2.5-3.0), which is quite similar to the data of Nuckton. 
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OSA INSULIN RESISTENCE AND DIABETES 
   OSA has been linked to diabetes mellitus. In a cross-sectional study, up 
to 23% of a diabetic population were found to have OSA.(32) Einhorn et al, 
found that 48% of diabetic patients had OSA with AHI ≥ 10/hr.(33) 
Conversely, there is a high prevalence of DM or insulin resistance in OSA 
patients. In a large clinic-based cross-sectional study, 30.1% of OSA patients 
had Type 2 DM, while 20% had impaired glucose tolerance.(34) Meta analysis 
has found that moderate-to-severe OSA was associated with an increased 
incidence of Type 2 DM.(35)  
   One study reported that the number of hypoxic episodes correlated with 
insulin resistance,36 with another showing a modest correlation between AHI 
and fasting insulin, but not fasting blood glucose levels.37 Some data shows a 
reduction in insulin resistance in obese patients with OSA and type 2 diabetes 
treated with CPAP,38whereas some found that while CPAP improved 
hypertension and daytime sleepiness, it will not alter insulin resistance.39 A 
systematic review and meta-analysis shows inconsistent results with CPAP 
treatment and insulin resistance, may be because of poor compliance with 
CPAP or irreversible changes associated with OSA(40) 
 OSA AND DYSLIPIDEMIA 
 Dyslipidemia, is defined as abnormally elevated total cholesterol or 
triglycerides with or without a corresponding significantly reduced high density 
lipoprotein (HDL). It is associated with progressive atherosclerosis in 
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susceptible individuals (44) Recently, there is a rejuvenated interest on the role 
of OSA in the development of metabolic syndrome including dyslipidemia, a 
surrogate marker for atherosclerosis. 
 
 
 
 
Figure 4 
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OSA AND HYPERTENSION 
   In normal individual there will be nocturnal decrease in the blood 
pressure and this seems to be altered in patients with OSA, Night-time BP may 
reflect cardiovascular risk as well as day-time BP, and alteration in the night 
time decrease has been shown to increased cardiovascular adverse events.(43) 
 
 
 
 
Figure 5 
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 The large prospective Sleep Cohort Study, showed a preventive role of 
CPAP in reducing new hypertension cases. This study reported a lower 
incidence of newly diagnosed HTN in those OSA patients who tolerated CPAP. 
Although long term outcomes is less clear several studies has shown a acute 
decrease in blood pressure with effective CPAP treatment.(14) 
OSA and hypothalamic pituitary adrenal axis 
  The hypothalamic–pituitary–adrenal (HPA) axis plays an important role 
in pathogenesis of obesity, and visceral fat distribution.45 The hypoxemia, brief 
arousals, and sleep fragmentation in OSA alter normal function of the HPA 
axis.45 Sleep deprivation is itself associated with pulsatile cortisol release, 
increased thyrotropin concentration, and the increased activity of the 
sympathetic nervous system as measured by heart rate variability and reduced 
glucose tolerance.(46,47) 
  A study involving 24 hours cortisol measurement shows that obese non 
apneic patients has low cortisol secretion and apneic patients has increased 
secretion and that returned to normal with CPAP therapy.(48) Carneiro et al. 
showed that 24 hour heart rate was more in patients with OSA and no 
differences in morning or evening cortisol levels between obese patients with 
and without OSA.. However, those with OSA showed a reduction in heart rate 
and greater cortisol suppression after dexamethasone, after 3 months of CPAP 
treatment and the greater dexamethasone suppression correlated with pre-
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CPAP AHI.49 The authors concluded that those with OSA suffer from 
abnormally high activation of both the sympathetic nervous system and HPA. 
OSA and inflammation 
  Inflammatory component appears to be the part of OSA, although the 
exact mechanisms remains unclear. Obesity itself appears to be a 
proinflammatory condition, although the effect of weight reduction on 
inflammation remains unclear. Snoring produces vibratory trauma and that is 
associated with tissue injury in the upper airway, which will cause elevated 
interleukin-8 levels.(50) Oxidative stress occurs because of repetetitive hypoxia 
and reoxygenation in OSA and there will be production of reactive oxygen 
species. This will activate an inflammatory response among patients with 
OSA...(51) .52 
 ROS has many important signaling properties and trigger inflammatory 
pathwaysthat may activate multiple proinflammatory cytokines, including 
tumor necrosis factor-α (TNF-α), inter-leukin-6 (IL-6), and IL-8 1.53 The 
proinflammatory transcription factor NF-κB is involved in the transcription of 
multiple genes involved in inflammation, metabolic syndrome, and 
atherosclerosis.54Repetitive hypoxia and reoxygenation causes increased levels 
of NF-κB in neutrophils and monocytes55 that correlate with OSA severity and 
are reduced with treatment by CPAP.56 
C-reactive protein (CRP) a biomarker of inflammation is produced in 
response to IL-6. It is an important marker in both cardiovascular disease and 
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the metabolic syndrome. CRP is 2.8 times higher in patients with metabolic 
syndrome.(57) pharmacologic reduction of CRP levels will lower 
cardiovascular risk. CRP is also elevated in obese patients independent of 
OSA. some studies have established independent association between osa and 
CRP levels after controlling for body mass index. (58) another study comparing 
CRP levels with different OSA severity matched for age and BMI found no 
increase in CRP and attributing elevation of CRP to the obesity and not 
OSA.(59)Studies on the effects of treatment are equally conflicting. Some 
studies shows reduction of CRP with CPAP treatment while some shows no 
change. 
OSA and SLEEP DEPRIVATION   
 Sleep deprivation is also a key component in OSA. Spiegel et al. 
showed that acute sleep deprivation in healthy young men will cause reduced 
serum levels of leptin, increased levels of ghrelin, and increased appetite. 
Higher glucose levels will be induced by sleep deprivation and alters glucose 
homeostasis, which will cause high glucose levels, insulin resistance, and risk 
of diabetes.60 It is known that CPAP treatment will reduce sleep deprivation 
among patients with OSA,61 but it is not known whether reduction in sleep 
deprivation is the one which will cause the normalization of metabolic 
parameters after CPAP treatment. Sleep deprivation in and of itself seem to be 
proinflammatory. Meier-Ewert et al. showed that elevated CRP levels are noted 
in those with an 88-hour period of sleep deprivation and a 10-day period of 
sleep restriction to 4 hours per night was62. IL 6 levels are also elevated in 
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those with 12-day period of sleep restriction and a trend toward higher CRP 
levels.  
IMPORTANCE OF CONFOUNDING FACTORS 
 Since cardiovascular disease and obstructive sleep apnea has common 
risk factors like age, gender, race/ethnicity, and obesity, these could confound 
the observed associations.63 Patients with obstructive sleep apnea were 
generally unhealthy and that also must be taken into account. One study 
pointed out that risk of 10 year cardiovascular disease was 30 percent among 
patients with OSA..64 
 Large-scale epidemiologic studies have confirmed that obstructive sleep 
apnea has been independently associated with cardiovascular disease, with 
proper statistical control for known confounding factors.65 In one of studies, 
risk of stroke or death was increased by obstructive sleep apnea (hazard ratio = 
1.97; 95% CI: 1.12– 3.48) independently of other risk factors like age, sex, 
race, smoking, alcohol consumption, body mass index, atrial fibrillation 
diabetes mellitus, dyslipidemia,, and hypertension. Another study shows that 
patients with an apnea hypopnea index (AHI) ≥ 20 had significantly greater 
odds for stroke than patients without sleep apnea (AHI < 5).66 
OSA AND SYMPATHETIC NERVOUS SYSTEM ACTIVITY  
  Studies showed that patients with sleep apnea were characterized by 
higher levels of sympathetic nervous system activity during wakefulness as 
well during sleep, relative to healthy controls. 67 During apnea events, oxygen 
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levels will decrease and carbon dioxide levels will increase commensurately, 
which will activate the sympathetic ner vous system. Higher level of 
sympathetic nervous system activity induced blood vessel constriction, with 
blood pressure rising to 250/150 mm Hg. Those patients also exhibited faster 
heart rates during wakefulness.  
Sleep Apnea and Cardiovascular Disease 
 In the Sleep Heart Health Study with a sample of 6,424 community 
based population who underwent home polysomnography, shows increased 
risk of coronary artery disease, congestive heart failure, and stroke among 
patients with severe obstructive sleep apnea. Specific analysis of the Sleep 
Heart Health Study shows that individuals with obstructive sleep apnea had 4 
times increased risk for atrial fibrillation (adjusted OR = 4.02; 95% CI: 1.03–
15.74).68 The Sleep Heart Health Study also revealed that odds for coronary 
heart disease (OR = 4.02; 95% CI: 1.03–15.74) and tachycardia (OR = 3.40; 
95% CI: 1.03–11.20) were greater among the individuals with obstructive sleep 
apnea.69 
 The exact underlying mechanism which will explain the underlying 
association between OSA and cardiovascular disease is not exactly understood 
several hypothesis have been proposed. These include sustained sympathetic 
activation,70 and oxidative stress, with formation of reactive oxygen species 
which will cause consequently vascular inflammation from the apnea hypoxia 
and reoxgenation cycles.71 
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    Repetitive apneic/hypopneic events along with ensuing arterial 
desaturation will cause activation of the sympathetic nervous system.71 This 
will lead to increases in systolic blood pressure which will lead to 
hypertension. Bradyarrhythmias are much more common than tachyarrhythmia 
which might be the resulting effect of an increase in vagal tone because of the 
stimulation of receptor sites in the upper airway.72 Disorders in coagulation 
factors, endothelial damage, platelet activation may also cause increase in 
inflammatory mediators.72Patients with obstructive sleep apnea have greater 
elevated endothelin levels and that is believed to impair blood pressure 
regulation as well. Elevated endothelin levels will return To normal with 
effective CPAP treatment.  
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It is proposed that hypoxia observed in sleep apnea will promotes the formation 
of reactive oxygen species, during the reoxygenation period which will activate 
the transcriptional activator hypoxia-inducible factor 1 (HIF-1).72 It has also 
been suggested that transcription factors, which elicit inflammatory pathways 
are also activated, which will affect inflammatory and immune responses by 
promoting activation of platelets endothelial cells and leukocytes..70  
Proinflammatory cytokines released will cause endothelial injury and 
dysfunction leading to cardiovascular morbidity. 
 This chain of events, occurring during obstructive sleep apnea will 
provoke atherogenic insult.71. These insults occurs before onset of disease since 
symptoms usually starts after 45 years.71 Some atherogenic processes are 
permanent but CPAP treatment will reduce progression.72 Using CPAP 
therapy, there is significant reductions in levels of C-reactive protein and 
interleukin-6,72 so sleep disorder to be diagnosed as early as possible to retard 
the progression of disease. Some studies shows positive results, like reduced 
systolic blood pressure, improves left ventricular systolic function, and 
increased ejection fraction on patients on CPAP therapy of patients with OSA 
and heart failure. 
The relationships between obstructive sleep apnea and cardiovascular 
disease are rather complex. Several systematic studies are necessary to look for 
these relationships.  
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POTENTIAL BENEFITS OF SLEEP APNEA TREATMENT 
   Clinical trials involving the use of CPAP or bilevel PAP therapy have 
shown positive results. CPAP treatment is very effective in improving quality 
of life and left ventricular ejection fraction and, lowers blood pressure and 
sympathetic activity, and reduces mortality among patients with congestive 
heart failure.(14) 
  Among patients with coronary artery disease, CPAP treatment 
significantly reduces risks of acute coronary syndrome, cardiovascular death 
and hospitalization for heart failure. Moreover, CPAP therapy has significant 
effects on lipid levels. CPAP studies show significant improvement in left 
ventricular function and insulin sensitivity and with a corresponding decrease 
in blood pressure.(14) 
  The Third Report of the Expert Panel on Detection, Evaluation, and 
Treatment of High Blood Cholesterol in Adults (ATP III) identifies the 
metabolic syndrome as a important target of risk-reduction therapy. It is 
recommended by them that patients meeting criteria for the syndrome receive 
adequate treatment aimed at reducing obesity through lifestyle modifications 
like increased physical activity and improved dietary habits. 
  Evidence suggests that weight loss among overweight and obese 
individuals reduces blood pressure, and improves blood glucose levels and 
improves lipid profiles. Behavioural therapy is first option and 
Pharmacotherapy is recommended only for those individuals who do not 
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respond positively to behavioral therapies. As gradual sleep loss in the 
population may be because of sequaelae of sleep apnea or behaviorally 
determined it is a strong determinant of insulin resistance and individuals at 
risk for developing cardiovascular disease should be encouraged not to 
decrease their sleep time. 
 
 
 
 
  
Figure 8 
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AIM AND OBJECTIVE 
PRIMARY OBJECTIVE 
  
  To estimate the prevalence of metabolic syndrome in patients with and 
without OSA in a hospital based population of tertiary healthcare centre in 
South India.  
 
SECONDARY OBJECTIVE 
  
 To investigate the association of metabolic syndrome and its 
components in patients with and without OSA. 
  To assess anthropometric indices as an indicator of apnea hypopnea 
index severity. 
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MATERIALS AND METHODS 
DEFINITION 
METABOLIC SYNDROME 
   As per modified NCEP ATPIII criteria (2005 REVISED definition) 
metabolic syndrome is defined as three out of five of the following features, 
 1. Abdominal Obesity (waist circumference >=90 cm for asian 
males,>=80 cm in asian females),  
 2. Hyperglycemia (fasting glucose>=100mg/dl or on treatment)  
 3. Hypertriglyceridemia (triglyceride >= 150mg/dl or on treatment) 
 4. Decreased HDL cholesterol ( <40mg/dl(M), <50mg/dl(F)) 
 5. Hypertension. (systolic >= 130mmHg or diastolic >= 85mm Hg) 
OBSTRUCTIVE SLEEP APNEA 
   OSA was defined as apnoea hypopnea index>5 events/h. Severity of 
OSA was graded as 
 mild OSA >=5 <15 events/hr 
 moderate OSA >=15 <30 events/hr  
 severe OSA AHI>=30 events/hr  
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STUDY DESIGN  
  It is a prospective cross sectional observational study to estimate 
prevalence of metabolic syndrome in patients with obstructive sleep apnea. 
 
TIME PERIOD 
 April 2017 to April 2018 
STUDY CENTRE 
  Rajiv Gandhi Government General Hospital 
STUDY POPULATION 
  Patients attending OPD of department of thoracic medicine in Rajiv 
Gandhi Government General Hospital with excessive day time sleepiness and 
sleep disturbances 
SAMPLING METHOD 
  Consecutive sampling 
Sample size calculation: 
  To test the difference of 30% prevalence of metabolic syndrome 
between the subjects with OSA and without OSA groups at 5% level of 
significance and 80% power we need sample size of 36 in each group (36 
subjects with OSA and 36 subjects without OSA). 
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Calculation: 
݊ = ൫௓భషഀ/మା௓భషഁ൯
మ[௣భ(ଵି௣భ)ା௣మ(ଵି௣మ)]
(௣భି௣మ)మ   
Standard normal value for 5% level of significance = Z1-α/2 =1.96 
Standard normal value for 80% power, Z1-β =0.84  
݊ = (ଵ.ଽ଺ା଴.଼ସ)మ[଴.଼଴(ଵି଴.ଶ଴)ା଴.ହ଴(ଵି଴.ହ଴)](଴.଼଴ି଴.ହ଴)మ  = 36 
ETHICAL CLEARANCE: APPLIED 
CONSENT 
 Informed written consent will be obtained from all patients. 
SAMPLE SELECTION 
INCLUSION CRITERIA 
 Willing for informed written consent 
 Males and females aged 30-65 yrs  
 Attending thoracic medicine outpatient department with sleep 
disturbances 
EXCLUSION CRITERIA 
 Not willing for informed written consent for the study 
 Patients having chronic renal failure, 
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  chronic liver disease, 
 facial anamolies 
  hypothyroidism  
  on harmone replacement therapy or steroids 
STUDY PROTOCOL 
 Patients attending the thoracic medicine OPD with complaints of sleep 
disturbances will be selected for the study as per inclusion/exclusion criteria 
and informed written consent will be obtained. 
 A detailed history, 
 Presenting history:  
Chief complaints, ho snoring excessive daytime sleepiness  
 Past history  
 Treatment history 
  H/O drug intake for any disease 
 Personal history 
Smoking history, alcoholism, occupation 
 FAMILY HISTORY  
 Diabetes hypertension cardiovascular disorders  
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 Comorbidities 
 DM/SHT/CAD/COPD/BA/Neurological diseases will be obtained. 
 clinical examination  
All the patients will undergo clinical examination of all the systems. Facial 
anamolies will be ruled out 
Anthropometric Measurements 
 All measurements were made with standard techniques. weight by 
digital scales (to within 100 g, without heavy clothing)height barefoot by 
stadiometer, waist circumference was measured mid-way between the lowest 
rib and the iliac crest with the subject standing at the end of gentle expiration. 
Body mass index 
 The body mass index of the study population was calculated using the 
quetlet index. 
 Body mass index= weight in kg/height in m2 
Neck circumference 
 Neck circumference was measured in the midway of the neck, between 
mid-cervical spine and mid anterior neck, to within 1 mm, with non-stretchable 
plastic tape with the subjects standing upright. In men with a laryngeal 
prominence (Adam's apple), it was measured just below the prominence. 
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Epsworth sleepiness scale  
  It is an eight-item, self administered questionnaire, with a total score 
ranging between 0 and 24. A score of greater than 10 indicates subjective 
excessive day time sleepiness.  
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Modified Mallampati Scoring 
 MMC assessment was performed with the patient sitting upright with his 
or her mouth maximally opened and tongue protruded without phonation. The 
participants were assigned to four classes 
Class I: Soft palate, fauces, pillars, and uvula are visible. 
Class II: Soft palate, fauces, and uvula are visible. 
Class III: Soft palate and base of uvula are visible. 
Class IV: Soft palate is not visible at all.  
Blood pressure 
  Blood pressure will be measured for all the patients by digital 
sphygmomanometer with the patient in sitting position in the right arm 
Polysomnography assessment  
  Polysomnography was conducted on the sleep lab of department of 
thoracic medicine madras medical college. The following parameters were 
monitored: frontal, central and occipital EEG, electrooculogram (EOG), 
submentalis EMG, nasal and oral airflow, anterior tibialis EMG, body position 
and electrocardiogram. Additionally, thoracic and abdominal movements were 
recorded by inductance plethysmography. Oxygen saturation (SpO2) was 
monitored using a pulse oximeter. The tracing was scored using 30 second 
epochs. After the overnight fasting blood samples will be taken for fasting 
blood glucose lipid profile (total cholestrol, HDL,LDL) 
ANALYSIS PLAN: 
 All analysis will be performed with SPSS version 14.0 and p<0.05 will 
be  considered significant. 
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RESULTS 
PATIENT CHARACTERISTICS 
     A total of 108 patients attending thoracic medicine outpatient 
department with sleep disturbances were included in the study after satisfying 
the inclusion and exclusion criteria  
GENDER DISTRIBUTION OF STUDY POPULATION 
  Out of the 108 patients included in the study 47 were females and 61 
were males. 
                                          TABLE 1 
 Frequency Percentage 
(%) 
Male 61 56.5 
Female 47 43.5 
total 108 100 
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DESCRIPTIVE STATISTICS OF STUDY POPULATION BASED ON 
GENDER 
TABLE 4 
CHARACTERISTICS MALE (n=61) 
mean(SD) 
Female(n=47) 
mean(SD) 
AGE 43..4(6.93) 45.3(5.89) 
BMI 29.7(2.44) 31.3(4.38) 
ABDOMINAL 
CIRCUMFERENCE 
104.7(11.23) 111.3(12.85) 
NECK 
CIRCUMFERENCE 
39.9(4.99) 38(3.92) 
ESS 13.1(6.80) 12.4(6.47) 
LOWEST SO2 85.1(16.16) 85(17.91) 
 
AGE 
  Mean age of both males and females was around 44.  
BMI 
  Mean BMI for males is 29.7 and for females is 31.3. 
ABDOMINAL CIRCUMFERENCE 
  Abdominal circumference of females was slightly greater than that of 
males. For males mean abdominal circumference was 104.7 and females it was 
111.3 
 Neck circumference 
   Neck circumference was almost 38 for both males and females 
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EPSWORTH SLEEPINESS SCORE 
  ESS was around 13.1 for males and 12.4 for females TABLE 5  
Descriptive statistics of clinical and laboratory findings in study group 
TABLE 5 
 With OSA 
(n = 69) 
WITHOUT OSA 
(n = 39) 
AGEa 44.6 (7.0) 43.6 (5.7) 
SEX (Female)c 30 (43.5) 17 (43.6) 
NECK CIRCUMFERENCE b 41 (7) 35 (2) 
ABDOMINAL 
CIRUMFERENCE b 
114 (22) 98 (11) 
BMI b 31.1 (3.7) 29.0 (2.5) 
ESS b 16 (6.5) 6 (4) 
SBP b 130 (20) 124 (15) 
DBP b 90 (10) 80 (14) 
TRIGLYCERIDE b 160 (38.5) 160 (30) 
HDL b 38 (7) 50 (13) 
FBS b 106 (27) 96 (35) 
 
a Mean (SD) for normally distributed data 
b Median (IQR) for skewed data 
c n (%) for categorical data 
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Distribution of mild moderate severe osa among study group 
 Of the 108 patients who have undergone polysomnography around 49 
patients have no OSA and 59 patients have OSA. Of the 59 patients around 22 
patients have AHI in the range 5-15 and 25 patients have AHI in range of 15-
30 and 12 patients have AHI more than 30. 
TABLE 6 
 Frequency (n=108) Percentage (%) 
No OSA (AHI <5) 49 45.4 
Mild OSA (AHI 5-15) 22 20.4 
Moderate OSA (AHI 15-30) 25 23.1 
Severe OSA (AHI >30) 12 11.1 
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Prevalence of metabolic syndrome among study group 
  Of the 59 patients with OSA around 57.4 percent has metabolic 
syndrome. 
 
 
  
57.4 %
Prevalence of Metabolic Syndrome
Figure 13 
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Prevalence of Metabolic Syndrome Among Study Groups 
TABLE 7 
 Metabolic Syndrome p-valuea 
 Present 
n 
Absent 
n 
No OSA (AHI <5) 17( 34.7) 32 (65.3) 
0.001 
Mild OSA (AHI 5-15) 11(50) 11(50) 
Moderate OSA (AHI 15-30) 22 (88) 3 (12) 
Severe OSA (AHI >30) 12 (100) 0  
 
 aChi-square test was used to test the proportional difference between the 
different groups. The p-value of 0.001 which is less than the 0.05 level of 
significance implies that there is significant association among OSA status and 
Metabolic syndrome. 
 Prevalence of metabolic syndrome among patients without OSA was 
34.7 percent. Among the mild OSA patients prevalence was 50 percent 88 
percent in moderate OSA group and 100 percent in severe OSA group. Chi 
square test shows a significant association with a p value of less than 0.001 
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SYSTOLIC BP AMONG STUDY GROUPS 
TABLE 8 
SYSTOLIC BP WITH OSA WITHOUT OSA p-valuea 
<130 36 (58.1) 26 (41.9) 
0.143 
>=130 33 (71.7) 12 (28.3) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. The p-value of 0.143 which is greater than the 0.05 level of 
significance signifies that there is no significant association among OSA status 
and systolic blood pressure. 
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DIASTOLIC BP AMONG STUDY GROUPS 
TABLE 9 
DIASTOLIC BP WITH OSA WITHOUT OSA p-valuea 
<85 25 (49) 26 (51) 
0.002 
>85 44 (77.2) 12 (22.8) 
 
a Chi-square test was used to test the proportional difference between the 
groups. Since, the p-value of the test is less than the 0.05 level of significance, 
it can be concluded that there is a significant association among OSA status 
and diastolic blood pressure. 
 
 
0
10
20
30
40
50
60
70
80
90
<85 >=85
Pe
rc
en
ta
ge
OSA Status
Diastolic BP
With OSA
No OSA
Figure 15 
 
49
TABLE 10 
FBS AMONG STUDY GROUPS 
FBS WITH OSA WITHOUT 
OSA 
p-valuea 
>100 30 (60) 20 (40) 
0.435 
<100 39 (67.2) 19 (32.8) 
 
aChi-square test was used to test the proportional difference between the 
different groups. From the above the above table, it is concluded that there is 
no significant association among the OSA status and FBS as the p-value of the 
test is greater than the 0.05 level of significance. 
 
 
 
0
10
20
30
40
50
60
70
80
>=100 <100
Pe
rc
et
na
ge
OSA Status
FBS
With OSA
No OSA
Figure 16 
 
50
TABLE 11 
Abdominal Circumference AMONG STUDY GROUP 
HDL WITH OSA  WITHOUT OSA p-valuea 
>90 FOR MALES  
>80 FOR 
FEMALES 
69 (65.1) 37 (34.9) 
0.058 
<90 FOR MALES 
<80 FOR 
FEMALES 
0 2 (100) 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of 0.058 which is greater than the 0.05 level of 
signifies indicates that there is no significant association between Abdominal 
Circumference and the OSA Status. 
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TABLE 12 
Lowest desaturation among study groups 
 With OSA Without OSA p-valuea 
<95 62 (93.9) 4 (6.1) <0.001 
>95 7 (16.7) 35 (83.3) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of <0.001 which is less than the 0.05 level of signifies 
indicates that there is a significant association between lowest desaturation and 
the OSA Status. 
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Mallampati grading among study group 
TABLE 13 
 With OSA Without 
OSA 
p-valuea 
Grade 1 and 
2 
19 (38) 31 (62) <0.001 
Grade 3 and 
4 
50 (86.2) 8 (13.8) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of <0.001 which is less than the 0.05 level of signifies 
indicates that there is a significant association between mallampati grading and 
the OSA Status. 
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TABLE 14 
TRIGLYCERIDES WITH OSA WITHOUT OSA p-valuea 
<150 23 (65.7) 12 (34.3) 
0.784 
>150 46 (63) 27 (37) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of 0.784 which is greater than the 0.05 level of 
signifies indicates that there is no significant association between triglycerides 
and the OSA Status. 
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TABLE 15 
HDL AMONG STUDY GROUP 
HDL WITH OSA WITHOUT OSA p-valuea 
<40 FOR MALES  
< 50 FOR 
FEMALES 
51 (86.4) 8 (13.6) 
<0.001 
>40 FOR MALES 
>50 FOR 
FEMALES 
18 (36.7) 31 (63.3) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of <0.001 which is less than the 0.05 level of signifies 
indicates that there is a significant association between HDL and the OSA 
Status. 
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TABLE 16 
Ahi and neck circumference 
Neck Circumference Ahi<5 Ahi>=5 p-valuea 
>43cms/M &>37cms/F 5 (9.1) 50 (90.9) 
<0.001 
<43cms/M &<37cms/F 44 (83) 9 (17) 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of <0.001 which is less than the 0.05 level of  
significance indicates that there is a significant association between Neck 
circumference and AHI. 
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TABLE 17 
Ahi and abdominal circumference 
Abdominal 
circumference 
Ahi<5 Ahi>5 p-valuea 
>90 males &> 80 
females 
47 (44.3) 59 (55.7) 0.117 
<90 males&<80 
females 
2 (100) 9 
 
a Chi-square test was used to test the proportional difference between the 
different groups. p-value of 0.117 which is greater than the 0.05 level of 
signifies indicates that there is no significant association between abdominal 
circumference and AHI 
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Correlation of Anthropometric Measurements with AHI: 
 Correlation between Abdominal circumference and AHI is 0.355 with 
the p-value of <0.001. 
 
Correlation between Neck circumference and AHI is 0.639 with the p-
value of  <0.001 
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Correlation between ESS and AHI is 0.830 with the p-value of <0.001. 
 
Comparison of anthropometric indices with AHI  
TABLE 18 
 
 Odds Ratio* (95% CI) p-value 
BMI 1.24 (1.08, 1.42) 0.003 
Neck Circumference  1.87 (1.47, 2.40) <0.001 
Abdominal Circumference 1.11 (1.06, 1.16) <0.001 
 
 Odds ratio for BMI and AHI was 1.24 and neck circumference odds 
ratio was 1.87 and odds ratio of abdominal circumference was 1.11 with both 
neck circumference and abdominal circumference has a p value of less  
than 0.001  
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ROC CURVE FOR FEMALES COMPARING BMI ABDOMINAL 
CIRCUMFERENCE AND NECK CIRCUMFERENCE WITH AHI 
SEVERITY 
 
  
 
60
ROC CURVE FOR MALES COMPARING AHI WITH ABDOMINAL 
NECK CIECUMFERENCE AND BMI 
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STATISTICS OF ROC CURVE ANALYSIS 
TABLE 19 
 
 Neck 
circumference  
Abdominal 
Circumference 
BMI 
Male Female Male Female Male Female 
Area Under the 
ROC Curve 
0.935 0.886 0.724 0.857 0.648 0.691 
Cut-off value 37 36  99.5 111 28.75 30.5 
Sensitivity 0.897 0.900 0.641 0.800 0.872 0.633 
Specificity 0.818 0.882 0.636 0.882 0.500 0.647 
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Statistics of ROC curve analysis 
Neck circumference 
 Area under roc cure for males was 0.935 and females was 0.836. cut off 
value for neck circumference for males was 37and females was 36 and 
sensitivity and specificity was 89 and 81 for males and 90 and 88 for females 
  Abdominal circumference 
 Area under roc cure for males was 0.724 and females was 0.857.cut off 
value for neck circumference for males was 99.5 and females was 111.4 and 
sensitivity and specificity of 64 and 63 for males and sensitivity and specificity 
of females was 80 and 88 percent respectively. 
BODY MASS INDEX  
Area under roc cure for males was 0.648 and females was.0.691 cut off 
value for body mass index for males was 28.75 and females was 30.5 and 
sensitivity and specificity was 87 and 50 for males and 63 and 64 for females. 
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TABLE 20 
Linear regression model to show the relationship of OSA status with 
various component of metabolic syndrome 
Dependent variable β (95% CI for β) p-value 
Waist circumference 9.515 (5.035, 13.996) <0.001† 
FBS 1.244 (-8.505, 10.993) 0.801 
SBP 2.285 (-2.310, 6.879) 0.326 
DBP 3.864 (0.782, 6.946) 0.015† 
TG 12.807 (-9.174, 34.788) 0.251 
HDL -9.714 (-12.954, -6.475) <0.001† 
AHI 17.177 (13.167, 21.186) <0.001† 
 
 Multiple Linear regression was used to assess the relationship. All the 
models were adjusted for Age and BMI. Beta coefficient along with its 95% CI 
is presented. Beta coefficient is interpreted as the average change in the 
dependent variable between subjects with and without OSA status. 
† Significant correlation with OSA at 5% level of significance. 
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DISCUSSION 
  OSA is on increasing trend because of epidemic of obesity(1) In this 
study prevalence of metabolic syndrome was 57.4 percent among OSA group 
in south Indian hospital based population and 34.7 percent in the patients 
without OSA. Agarval et al reported prevalence of metabolic syndrome to be 
79 percent in north Indian hospital based population.studY.(73) 
Studies have shown increased prevalence of metabolic syndrome in 
north Indians compared to south Indians. (74) khan yesme et al have shown 
increased prevalence of metabolic syndrome among north indians and they are 
on increasing trend. The reason for difference in prevalence between north 
Indian study and our study may be because of that reason.  
 Population based studies has shown prevalence of metabolic syndrome 
in the Indian population to be 20 percent. Since our study is a hospital based 
study prevalence is slightly higher than those of population based studies.  
  Almost all these studies considered the variables involved in metabolic 
syndrome individually. Only a few investigations to date have evaluated the 
association of OSA with metabolic syndrome as a whole. Coughlin et al.23 in a 
sample of 61 men with OSA and 43 control subjects, found that OSA was 
independently associated with hypertension, high fasting glucose and 
triglyceride levels, low HDL-cholesterol level, and a trend toward high HOMA 
values, with an odds ratio of 9.1 for total metabolic syndrome.(76) However, 
they did not focus on the severity of OSA. Lam et al.(85) monitored 255 
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randomly selected Chinese volunteers for metabolic profile and sleep 
characteristics by overnight polysomnography and reported that OSA was 
associated with all the components of metabolic syndrome, and that metabolic 
syndrome was an independent predictor of OSA. The main value of the present 
study is our finding that with an increase in the severity of OSA, there is a 
significant increase in the prevalence of metabolic syndrome. In our study 
prevalence of metabolic syndrome in patients with mild osa is 50 percent, 
moderate osa is 88 percent and with severe osa is 100 percent and there is 
significant association between osa and metabolic syndrome.  
 Our study analyzed various anthropometric measures and their 
associations with the presence, as well as the severity, of OSA in the south 
indian adult population. To the best of our knowledge, this is the first study to 
determine the cut-off values for predicting the risk of OSA in anthropometric 
indices including, neck circumference, waist circumference, and body mass 
index, in an south indian population. In this study, patients with OSA had 
statistically significantly higher values of neck circumference waist 
circumference and body mass index compared to the patients without OSA. All 
of the anthropometric indices (NC, WC, and BMI) were significantly correlated 
with the severity of OSA. These results were similar to those of previous 
studies. Obesity, especially central obesity, is a major risk factor for OSA. 
simple anthropometric indices like waist cirumference, body mass index, and 
the neck circumference, are widely used as markers of obesity or central 
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obesity. Clinically, neck circumference has been reported to be a useful 
predictor of OSA. 
  In our study, a logistic regression analysis showed that NC was a more 
potent predictor for the presence of OSA compared to WC and BMI.. scatter 
plot diagram also shows significant association of neck circumference with 
apnea hypopnea index compared with BMI and abdominal circumference. 
Neck circumference is a better predictor of apnea hypopnea index in both 
males and females. These results were similar to those of previous studies. 
Onat et al. [78] have reported that neck circumference contributes to metabolic 
syndrome more the waist circumference. Simpson and colleagues have 
evaluated the relationship between the severity of OSA and measures of 
regional obesity in a prospective observational study and found that neck 
circumference was significantly associated with OSA in both males and 
females.(77) Suhbey et al also demonstrated that neck cirmcumference is a 
better predictor of apnea hypopnea index severity.(78).  
Genetic and environmental influences determine body fat distribution 
and obesity severity. The cut off values of anthropometric indices may vary 
differently according to sex and ethnicity Recently, neck circumference has 
been identified as an index of central obesity and a potential predictor of OSA 
This may be because of the fact that recent studies have shown that neck 
circumference is a better predictor of central obesity than other variables(81)  
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 In our study ROC curve shows that neck circumference has better 
sensitivity and specificity in predicting apnea hypopnea index with sensitivity 
of around 90 percent and specificity of around 81 percent. Cizza et al. have 
reported that a neck circumference of ≥38 cm had a sensitivity of 54% and 58% 
and a specificity of 70% and 79% in predicting the presence of metabolic 
syndrome and OSAS, respectively [79]. Soylu et al.study shows that NC was a 
better predictor than waist circumference in determining OSA severity in 
Turkish adults (80). Accoerding to their study the optimal cut-off values of 
neck circumference for predicting OSA were 35.5 cm in females and 39 cm in 
males. Zhou et al. have reported that and that neck circumference values of 33 
cm for females and 37 cm for males are the optimal cut-off values for 
metabolic syndrome in adults from China and states that neck circumference 
predicts cardio-metabolic risks beyond the other anthropometric indices (81)  
 hyeon hyi kang reported that the optimal cut-off values of NC for 
predicting OSA were 34.5 cm in females and 38.75 cm in males in Korean 
population. Despite ethnic differences these studies shows relatively similar cut 
off values for neck circumference. In our study predicting cut off values for 
neck circumference are 36 for females and 37 for males which is also similar 
suggesting neck circumference can be used universally beyond ethnic 
differences. 
   Martin et al. have reported that a BMI>30 kg/m2 in both genders is 
associated with the development of OSA (82). Soylu et al. have shown that 
BMI values over 27.77 kg/m2 in females and over 28.93 kg/m2 in males 
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increase the risk of OSA in a Turkish population (81) In the study by hyong he 
hyang et al, the cut-off value for BMI as an OSA determinant was over 23.05 
kg/m2 in females and over 24.95 kg/m2 in males in a Korean population. In our 
study cut off values are 28.75 for males and 30.5 for males.(83) 
 Epsworth sleepiness score shows significant association with apnea 
hypopnea index and lower in patients with OSA compared to the patients 
without OSA. Our results are similar to the following studies. Lee sj et al 
reported a positive correlation between the ESS score and BMI, percentage of 
snoring time, minimum SpO(2) and time length of SpO(2) < 90%(84).Lowest 
desaturation was significantly associated with osa and may be that is the reason 
behind increased prevalence of metabolic syndrome variables. Ana safya et al 
have shown that there is a significant association between prevalence of 
metabolic syndrome and oxygen desaturation time.(82)  
Mallampati grading shows significant association with the metabolic 
syndrome. Nuckton et al30 prospectively assessed 137 patients attending a sleep 
clinic and reported an OR for OSA (defined as an AHI ≥ 5) of 2.5 (95% 
confidence interval [CI] 1.2-3.2) for each point increase in Mallampati class. 
The OR for Mallampati class was higher more than those of witnessed apneas 
and neck circumference. The authors concluded that the Mallampati class was a 
useful component of the clinical examination that had clinical value in 
predicting the presence of severity of OSA  Our results are also similar to  
them. Hence mallampati grading can be used as a bedside assessment of 
patients with OSA.  
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 We compared association of various variables of the metabolic 
syndrome with obstructive sleep apneA. of the various variables of metabolic 
syndrome like fasting blood glucose, blood pressure, hdl cholesterol and 
abdominal circumference diastolic blood pressure and hdl cholesterol shows 
significant association with metabolic syndrome with p value of less than 
0.005. These results are similar to that of parish at al where their study shows 
significant relationship between hypertension and OSA and not other 
variables(80) 
 One study reported that the number of hypoxic episodes correlated with 
insulin resistance,36 with another showing a modest correlation between AHI 
and fasting insulin, but not fasting blood glucose levels.37 Some data shows a 
reduction in insulin resistance in obese patients with OSA and type 2 diabetes 
treated with CPAP,38 whereas some found that while CPAP improved 
hypertension and daytime sleepiness, it will not alter insulin resistance.39.With 
our data we can come to a hypothesis that OSA is not independently associated 
with fasting blood glucose.. Follow up studies are needed to arrive at a 
conclusion.  
 In our study there is significant association between OSA and HDL 
cholesterol. There are only 4 randomized studies9,34–36 that evaluated lipid 
profile pre- and post- CPAP treatment in adults. With the exception of a 
clinical trial by Robinson et al., all studies involved a small sample size. Only 
Robinson et al. found a significant decrease in total cholesterol after CPAP, 
whereas three other studies did not find any changes in plasma lipids in 
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response to therapy.(86) further studies with large sample size in the asian 
population is needed to come to a conclusion.  
In our study OSA has been significantly associated with diastolic blood 
bressure. Baguet et al., using 24-hour ambulatory BP monitoring, exposed a 
substantial prevalence of OSAS-induced high BP occurring only during the 
night. Generally, high SBP is attributed to noncompliant, stiff arteries, whereas 
elevated DBP is related to the activation of the sympathetic autonomic nervous 
system. This augmented activity may be related to activation of chemoreceptors 
by intermittent hypoxia caused by the occurrence of apnea or hypopnea prior to 
the morning BP measurement. Furthermore, microarousals that usually end 
apnea events have also been implicated in the stimulation of sympathetic 
system, leading to BP elevation.(87) 
  The increasing prevalence of MS with increasi ng severity of OSA 
suggests an association of OSA with MS. However, obesity is a significant 
confounder in studies involving OSA and MS. Causative role cannot be 
inferred from this data alone, since, it is a common major risk factor for both 
conditions. 40-90 per cent obese individuals have Obstructive sleep apnea and 
about 70 per cent of Obstructive sleep apnea patients have obesity, Only a 
longitudinal study would be able to definitely prove whether Obstructive sleep 
apnea precedes and causes metabolic syndrome or vice versa, and whether 
obesity is a predisposing factor for both these conditions. 
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CLINCAL IMPLICATIONS OF THE STUDY  
  The clinical implications are that there is a high prevalence of metabolic 
syndrome in patients presenting to sleep clinics with symptoms suggestive of 
Obstructive sleep apnea, irrespective of whether they have obstructive sleep 
apnea or not. Simple indices like neck circumference, mallampati scoring and 
epsworth sleepiness score will help in accessing the severity of OSA and hence 
metabolic syndrome. 
   The prevalence of MS is even higher if they have obstructive sleep 
apnea. Metabolic syndrome and its components are more likely to be present in 
patients with obstructive sleep apnea and its prevalence will increase with 
increasing severity of obstructive sleep apnea.  
   Screening for metabolic syndrome and its components along with the 
work up of obstructive sleep apnea will allow early detection of these cases. 
This relationship of metabolic syndrome with obstructive sleep apnea can also 
explain the mechanism for increased mortality in patients with OSA.  
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LIMITATIONS OF STUDY 
  The present study has some limitations. Being a hospital-based study 
there was referral bias with more symptomatic patients with sleep disturbances 
likely to be referred to our hospital.  
  The non-OSA group did not reflect absolutely normal healthy 
individuals and they were more likely to have components of metabolic 
syndrome like hypertension, diabetes, dyslipidaemia and obesity than healthy 
volunteers. However, this will decrease the difference found between the two 
groups rather than increase it. 
  For an important potential confounder obesity, matching was not done. 
An ideal study design must have BMI matched controls to reduce 
confounding.. 
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STRENGTHS OF THE STUDY 
 The strengths of the present study include 
(i) a large sample size of 108 patients  
(ii)  OSA in control group has been excluded by performing a full 
overnight polysomnography study in each one of them;  
(iii)  obstructive sleep apnea has been diagnosed by level 3 study in 
all  
(iv)  use of AHI cut-off of ≥5 events/h in accordance with the results 
of the Sleep Heart Health Study  
(v)  inclusion of both males and females in the study so that can be 
applied to both groups 
 
 
 
 
 
 
 
 
 
 
74
CONCLUSION 
  In conclusion, our study showed that the prevalence of metabolic 
syndrome was higher in patients of OSA than controls the prevalence increased 
with increasing severity of OSA. 
 Of the variable parameters of metabolic syndrome diastolic BP and 
HDL cholesterol shows significant association with metabolic syndrome. 
Further follow up studies are needed to come to a conclusion.  
   Of the various anthropometric indices neck circumference shows 
significant correlation with metabolic syndrome. The cut off values of neck 
circumference are 36 for females and 37 for males. the cut off values of 
abdominal circumference are relatively same in different studies despite ethnic 
differences. 
  ROC curves shows neck circumference has better sensitivity and 
specificity than other anthropometric indices like body mass index and 
abdominal circumference. Mallamapati scoring and epsworth sleepiness score  
also shows significant association with OSA. 
 Hence we recommend that simple indices like neck circumference, 
mallampati scoring and epsworth sleepiness score must be done for all patients 
attending OPD with sleep disturbances and patients with OSA should be 
investigated for MS and vice versa, as early detection and correction may result 
in significant decrease in morbidity and mortality.  
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Even simple life style changes and behavorial changes will produce a 
great impact. CPAP treatment will cause significant reduction in cardiovascular 
mortality. Hence routine screening will help in diagnosing early and preventing 
many complications. 
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ABBREVATIONS 
 
AHI  - apnea hypopnea index  
AC  - abdominal circumference  
CPAP  - continous positive airway pressure  
DBP  - diastolic blood pressure 
NC  - neck circumference 
OSA  - obstructive sleep apnea 
OSAS  - obstructive sleep apnea syndrome 
ROS  - reactive oxygen species  
SBP  - systolic blood pressure 
WC  - waist circumference 
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PATIENT CONSENTFORM 
Study Detail : “TO INVESTIGATE THE ASSOCIATION OF 
METABOLIC SYNDROME AND ITS COMPONENTS IN 
PATIENTS WITH AND WITHOUT OSA 
 
Study Centre : Rajiv Gandhi Government General Hospital, Chennai. 
Patient’s Name : 
Patient’s Age : 
Identification Number: 
Patient may check (√) these boxes :a) I confirm that I have understood the purpose of 
procedure for above study. I have the opportunity to ask question and all my questions 
and doubts have been answered tomy complete satisfaction. ❏ 
b) I understand that my participation in study is voluntary and that I am free to 
withdraw at any time without giving reason, without my legal rights being affected. 
❏ 
c) I understand that sponsor of the clinical study, others working on the sponsor’s 
behalf, the ethical committee and the regulatory authorities will not need my 
permission to look at my health records, both in respect of current study and any 
further research that may be conducted in relation to it, even if I withdraw from the 
study I agree to this access. However, I understand that my identity will not be 
revealed in any information released to third parties or published, unless as 
required under the law. I agree not to restrict the use of any data or results that arise 
from this study. ❏ 
d) I agree to take part in the above study and to comply with the instructions given 
during the study and faithfully cooperate with the study team and to immediately 
inform the study staff if I suffer from any deterioration in my health or well being or 
any unexpected or unusual symptoms. ❏ 
e) I hereby consent to participate in this study. ❏ 
f) I hereby give permission to undergo detailed clinical examination, 
Radiographs,blood investigations and other procedures as required. ❏ 
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 Signature of Investigator: 
patient’s Name and Address:  
 Study Investigator’s Name: Dr.Suganya C 
  
EVALUATION FORM 
 
Name: 
Age: 
Sex: 
OP/Ip number: 
Presenting complaints: 
History of presenting illness: 
Past history: 
Treatment history: 
Smoking history: 
Personal history: 
Occupational history: 
CO-MORBIDITY: 
General examination: 
 Body Mass Index: 
 Waist circumference: 
 Neck circumference 
 Blood pressure: 
Systemic examination: 
Blood investigations: 
 COMPLETE BLOOD COUNT 
 RFT, LFT 
 RBS,FBS,PPBS 
 Fasting Lipid profile: triglyceride level 
  LDL cholestrol 
 HDL cholesterol: 
ECG 
Echocardiography:  
Polysomnography 
 
s no AGE SEX BMI NECK 
CIRC
ABD 
CIR
ESS AHI
LOWEST 
DESATURATI
ON
TRIG HDL systo
lic
FBS MS dias 
bp
mallam
bati
1 57 F 40 38 125 21 25 52 118 38 140 129 YES 90 3
2 40 M 26 35 118 21 30 36 85 25 100 196 NO 60 2
3 40 F 33 38 122 18 26 39 300 24 140 62 NO 90 4
4 42 M 29 44 114 24 35 64 439 26 120 96 NO 82 3
5 45 M 30 46 99 18 25 82 85 35 130 114 YES 80 2
6 53 M 30 44 114 16 24 49 250 35 150 145 YES 90 1
7 55 F 40 47 112 17 13 53 159 40 140 150 YES 110 3
8 34 M 34 44 100 23 17.6 91 171 30 120 74 NO 80 4
9 37 M 29 47 94 24 41 61 259 40 120 83 NO 80 2
10 40 F 23 36 86 3 0 97 159 40 120 79 NO 74 3
11 40 F 40 38 125 5 0 97 118 38 140 129 YES 90 4
12 50 F 29.7 37 102 21 18 87 118 38 140 91 YES 90 4
13 49 F 35 37 120 15 12 50 230 24 110 128 YES 80 3
14 43 F 34 37 120 21 12 87 150 37 130 117 YES 85 3
15 48 F 35 40 114 15 11 92 179 38 140 83 YES 90 3
16 41 F 33 40 129 17 16.8 84 154 42 110 91 YES 90 4
17 42 M 34 47 131 21 25 83 125 38 130 93 YES 90 2
18 40 M 30.5 44 114 14 40 60 170 35 140 110 YES 90 4
19 35 M 29 39 123 21 35 52 181 44 140 106 YES 90 3
20 30 F 28 47 127 21 10 75 200 42 130 105 YES 90 2
21 55 M 30 45 103 16 12 87 160 44 140 86 YES 90 4
22 57 M 31 40 95 24 40.1 83 160 35 140 110 YES 90 3
23 48 F 33 41 121 18 14 85 160 60 140 140 YES 90 4
24 48 M 34 44 114 12 14 87 170 38 135 110 YES 90 3
25 45 M 30 46 99 16 24 92 210 35 135 110 YES 90 4
26 45 M 30 42 99 5 0 92 170 35 140 120 YES 90 2
27 41 F 32 40 128 4 0 93 154 42 130 125 YES 90 3
28 44 M 33 47 131 18 9.4 93 164 38 130 95 YES 90 4
29 48 F 34 37 120 3 0 92 163 37 130 94 YES 90 3
30 42 M 26 47 132 18 27 82 140 43 110 97 NO 80 2
31 43 F 27 37 121 18 12 84 140 52 110 93 NO 80 1
32 55 M 28 45 103 18 25 86 145 43 110 93 NO 80 4
33 48 F 26 41 127 21 30 87 160 35 130 97 YES 100 3
34 50 F 28 40 95 18 15 95 140 47 110 97 NO 80 4
35 36 M 29 39 123 21 37 67 170 40 130 110 YES 90 3
36 48 M 35 44 114 14 14 92 140 45 110 96 NO 80 4
37 33 M 30 35 97 12 9 96 141 45 110 83 NO 80 3
38 48 F 24 40 129 17 16.8 84 154 42 140 93 YES 90 3
39 40 m 25 38 99 12 2 93 130 45 125 75 n0 70 2
40 35 m 28 38 100 9 1 96 128 45 123 75 no 76 3
41 52 f 27 40 110 9 2 96 145 45 140 106 no 80 2
42 32 m 26.5 33 92 8 2 90 150 42 110 86 no 70 1
43 50 f 27.5 33 90 6 2 98 160 55 120 103 no 80 2
44 40 m 24.5 34 94 6 2 95 142 42 120 120 no 80 1
45 31 m 31 32 98 4 2 96 120 58 110 95 no 70 3
46 40 f 26 34 110 8 4 98 130 55 120 96 no 80 2
47 40 m 28.5 38 96 4 3 98 145 45 120 124 n0 76 2
48 48 f 31 34 109 4 3 98 150 55 130 85 no 90 2
49 40 m 27 35 98 6 4 97 155 38 120 96 no 80 2
50 43 f 29 36 98 8 3 97 160 55 120 86 no 80 2
51 46 m 30 34 95 6 2 98 155 55 #### 106 yes 90 2
52 50 f 26 34 112 8 3 98 186 36 150 170 yes 90 2
53 56 m 25 35 85 8 4 98 165 50 135 86 no 90 2
54 45 f 27 34 90 4 2 98 155 45 120 85 no 75 2
55 50 m 26 35 95 8 3 98 167 55 110 86 no 70 1
56 46 f 27 32 106 4 1 98 178 50 110 107 no 70 1
57 50 m 30 38 110 2 2 98 176 50 140 117 yes 90 1
58 48 f 33 34 95 8 2 98 167 55 130 76 no 80 1
59 47 m 27 34 90 6 3 98 165 56 126 85 no 82 1
60 43 m 28 35 102 4 4 98 175 58 124 76 no 82 2
61 45 f 30 36 95 8 2 98 220 35 135 150 no 90 2
62 46 f 28 36 100 4 3 98 165 55 120 76 no 80 2
63 50 m 31 34 105 6 2 98 155 55 120 89 no 76 3
64 48 f 30 36 95 8 3 98 165 55 120 72 no 80 4
65 49 m 26 34 95 4 2 98 145 54 125 78 no 80 2
66 43 f 30 36 90 8 3 98 155 56 140 80 no 90 2
67 46 m 32 35 96 4 2 98 165 55 124 112 no 78 3
68 42 f 33 38 105 4 3 97 165 40 135 120 yes 80 3
69 43 m 30 32 124 8 4 96 175 42 140 130 yes 90 2
70 44 m 31 36 118 10 2 98 155 45 135 123 yes 80 2
71 35 f 32 34 106 12 4 98 180 50 136 107 yes 86 2
72 36 m 31 36 108 8 4 98 175 40 120 108 yes 75 2
73 37 m 30 34 103 6 3 97 178 55 135 120 yes 90 2
74 38 f 34 35 98 4 2 96 180 35 120 140 yes 80 1
75 37 m 33 32 95 5 4 95 176 50 134 90 yes 90 3
76 42 f 31 36 120 8 1 99 135 40 130 130 yes 96 2
77 48 m 30 35 89 10 0 98 132 55 110 170 yes 100 3
78 39 m 29 42 100 18 19 94 158 38 140 125 yes 80 3
79 50 m 31 45 110 12 35 90 160 20 150 106 yes 90 3
80 40 m 31 43 95 21 50 86 130 39 130 120 yes 84 3
81 38 m 30 40 102 18 17 90 128 38 150 94 yes 86 3
82 40 F 33 38 122 18 26 39 300 24 140 62 NO 90 4
83 42 M 29 44 114 24 35 64 439 26 120 96 NO 82 3
84 45 M 30 46 99 18 25 82 85 35 130 114 YES 80 2
85 53 M 30 44 114 16 24 49 250 35 150 145 YES 90 1
86 55 F 40 47 112 17 13 53 159 40 140 150 YES 110 3
87 34 M 34 44 100 23 17.6 91 171 30 120 74 NO 80 4
88 50 f 27.5 33 90 6 2 98 160 55 120 103 no 80 2
89 40 m 24.5 34 94 6 2 95 142 42 120 120 no 75 2
90 31 m 31 32 98 4 2 96 120 58 110 95 no 80 2
91 40 f 26 34 110 8 4 98 130 55 120 96 no 80 1
92 40 m 28.5 38 96 4 3 98 145 45 120 124 n0 80 2
93 45 M 30 46 99 18 25 82 85 35 130 114 YES 80 2
94 53 M 30 44 114 16 24 49 250 35 150 145 YES 90 1
95 55 F 40 47 112 17 13 53 159 40 140 150 YES 110 3
96 50 F 29.7 37 102 21 18 87 118 38 140 91 YES 110 4
97 49 F 35 37 120 15 12 50 230 24 110 128 YES 100 3
98 43 F 34 37 120 21 12 87 150 37 130 117 YES 100 4
99 48 F 35 40 114 15 11 92 179 38 140 83 YES 110 2
100 41 F 33 40 129 17 16.8 84 154 42 110 91 YES 90 3
101 40 M 30.5 44 114 14 40 60 170 35 140 110 YES 95 4
102 35 M 29 39 123 21 35 52 181 44 140 106 YES 95 3
103 30 F 28 47 127 21 10 75 200 42 130 105 YES 100 3
104 55 M 30 45 103 16 12 87 160 44 140 86 YES 90 4
105 57 M 31 40 95 24 40.1 83 160 35 140 110 YES 90 4
106 48 F 33 41 121 18 14 85 160 60 140 140 YES 90 4
107 48 M 34 44 114 12 14 87 170 38 135 110 YES 90 3
108 45 M 30 46 99 16 24 92 210 35 135 110 YES 90 4
